CDKL3

Across TCGA pan-cancer cohorts, CDKL3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CDKL3 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CDKL3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDKL3 expression acts as an unfavorable survival marker.

LUAD and PDAC are the cancer types where CDKL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.542	0.942	.002	30	view →
PDAC	OS	Median	III,IV	0.592	0.893	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CDKL3–LUAD (OS)

Open the LUAD breakdown →